Olanzapine Oral Dispersable

UNCONTROLLED WHEN PRINTED

Introduction

Olanzapine is a second generation antipsychotic agent that acts on multiple receptors (incl. serotonin and dopamine receptors), resulting in sedation
Onset of effect usually ~ 10 mins.

Indications

Disturbed and Abnormal Behaviour (RASS 1 ~ 2) where risk to safety is evident and the patient is able to tolerate or self-administer an oral wafer
Preferred first line sedation agent in frail patients and those with Dementia

Contraindications

Precautions / Notes

Sedation of any patient < 16 years of age –should prompt a prior ASMA consult wherever practicable.
Organic causes such as suspected sepsis, traumatic brain injury or spontaneous intra-cranial event must be considered unlikely
‘Agitated or Excited Delirium’, ‘Acute Behavioural Disturbance’ and ‘Drug Induced Psychosis’ are some alternative terms that may be used by other agencies
Effects may be amplified in patients with alcohol intoxication
Oral dispersible tablet may be dissolved in water (may slightly delay onset of action but still preferable in non-emergent cases)
Early monitoring as soon as practicable is required when administering Olanzapine; including SpO2, respiratory rate, pulse and blood pressure
SpO₂ and etCO₂ monitoring must be applied whenever level of consciousness drops (~RASS < 0)

Management

Adults < 70 years old:

10mg
Repeat once only after 15 mins if indicated to total maximum cumulative dose via all routes 20mg/24hrs.

Adults > 70 years old or frail:

5mg
Repeat once only after 15 mins if indicated to total maximum cumulative dose via all routes 10mg/24hrs.

Paediatric 6 - 15 years old, > 40kg:

5 - 10mg
Repeat once after 15mins if indicated to a total maximum cumulative dose via all routes 20mg/24hrs.

Paediatric < 40kg

Special Considerations

References

Presentation

5mg Oral Dispersible tablets in blister pack

OLZ1

Colour assist:

Directorate

Clinical Services

Responsible Manager

Head of Clinical Services

Date of Issue

Date of Expiry